Top Markets
#1 Akedo Akedo +136.52%
#2 TENDIES TENDIES +87.88%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +43.74%
#5 Bitway Bitway +27.02%
#6 Mubarak Mubarak +25.52%
#7 Cash Cat Cash Cat +23.53%
#8 Palladium Network Palladium Network +22.71%
#9 MultiversX MultiversX +20.20%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Beállítások
Nyelv
MAGYAR
Pénznem
USD
Téma
Mabpharm Limited Mabpharm Limited

Mabpharm Limited

2181
Helyezés a részvények között #17592
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research,... Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Részvényárfolyam
$0.05692717
Piaci kapitalizáció
$234.77M
Változás (1 nap)
0.00%
Változás (1 év)
-44.45%
Ország
CN
Kereskedés Mabpharm Limited (2181)

Kategória

Healthcare
Mabpharm Limited (2181) részvényárfolyamának története
Legmagasabb napi záróár: $0.06 ekkor: 2026-09-01

Legalacsonyabb napi záróár: $0.15 ekkor: 2019-05-01
Mabpharm Limited részvényárfolyamának története 2019 és 2026 között
Éves részvényárfolyam teljesítmény
Év Teljesítmény
2026 (TTM) -5.95%
2025 81.18%
2024 -37.02%
2023 15.39%
2022 -56.86%
2021 -14.35%
2020 6.38%
2019 0.00%
Hasonló cégek vagy versenytársak részvényárai
Vállalat Részvényár Változás 1év% Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $556.43 38.76%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 48.60%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $152.82 531.75%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.21 -10.03%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $757.71 8.20%
CH